CMC Risk Intelligence that Reveals What Can Fail - Before it Becomes Cost, Delay, or Liability

Your asset never enters generative AI.
NDA first.
Secure Tresorit™ encrypted exchange.

Who Do We Help?

Biopharma Counsel
Investors & Capital Principals
Founders & Innovators
Technical Leaders

Magnifying glass over team icon on digital globe

How We Help

Identify critical failure points and unsupported assumptions

Connect risk to mechanism, evidence gaps and controls

Quantify probability, delay and dollars-at-risk

Human-authored CMC risk intelligence - not generic consulting

Your asset never enters generative AI. All engagements operate under NDA, with secure, end-to-end (E2E) encrypted exchange exclusively through Tresorit™.

Why It Matters

Surface surprises early — not after execution

Expose liability before capital is committed

Strengthen CDMO and contract negotiation leverage

Improve confidence in cost, timeline and valuation assumptions

Identify which evidence most reduces uncertainty

Customizable Services

Independent analysis of formulation, process, manufacturing, scale-up, and regulatory risk - connecting technical failure mechanisms to evidence, controls, probability, and financial exposure.

Change Order Triggers

(Know what should trigger action before a problem occurs)

Technical Risks - Dollars-at-Risk

(Convert technical uncertainty into financial visibility)

Probability & Failure - Pathway Modeling

(undersatnd not only what could happen, but how likely it is and which pathway is most vulnerable)

No-Cost Protected First Look

Step 1. Request access to the secure encrypted exchange.

Step 2. Execute a no-cost mutual NDA

Step 3. Submit limited or redacted asset information through Tresorit.

Step 4. Receive a focused risk intelligence exhibit - NO COST.

The exhibit may identify a critical blind spot, unsupported assumption, evidence gap, failure mechanism, or control question.